Using engineered probiotics to reduce radiation injury effects
LR-IL-22 for Mitigation and Management of Radiation Injuries
This study is looking at a special probiotic that helps your gut heal after radiation treatment, especially if you've had damage to your intestines, and it aims to find out how well it works when combined with another probiotic to boost recovery.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10990525 on NIH RePORTER |
What this research studies
This research investigates the use of engineered Lactobacillus reuteri that produces IL-22 to mitigate damage caused by total or partial body irradiation, particularly focusing on the acute gastrointestinal syndrome. The approach involves oral administration of this probiotic to enhance recovery of intestinal stem cells and restore their function after radiation exposure. The study aims to understand the mechanisms behind this mitigation and improve the safety and efficacy of the treatment. By combining the engineered probiotic with another probiotic that stimulates recovery, the research seeks to enhance the therapeutic effects further.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced total or partial body irradiation, such as those undergoing radiation therapy for cancer.
Not a fit: Patients who have not been exposed to radiation or those with pre-existing gastrointestinal conditions unrelated to radiation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve recovery outcomes for patients suffering from radiation injuries.
How similar studies have performed: Preliminary data suggest that similar approaches using engineered probiotics have shown promise in mitigating radiation-induced damage, indicating potential for success.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Greenberger, Joel S — University of Pittsburgh at Pittsburgh
- Study coordinator: Greenberger, Joel S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.